Immunotherapy with chemo improves survival for aggressive relapsed lymphoma

Joshua Brody, Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, shared on LinkedIn:

“In relapsed aggressive lymphoma, adding bispecific CD3xCD20 immunotherapy to chemo DOUBLES Overall Survival and Complete Remissions! To 59%!

STARGLO trial treating patients at ~70 hospitals around the world including Mount Sinai.”

Read further.
Source: Joshua Brody/LinkedIn